Company intelligence / Profile preview

Mabion S.A.

Konstantynów Łódzki, Łódź Voivodeship, Polandmabion.eu ↗

Ownership: Private
Development stage: Commercial

Overview

Mabion has transitioned into a fully integrated biologics CDMO with a growing pipeline of client projects. Its lead proprietary program, MabionCD20, has received orphan drug designation from the FDA for autoimmune hemolytic anemia and membranous nephropathy. The company also collaborates on vaccine antigen production with Novavax and other partners.

Recent financial results indicate strong profitability and business growth driven by new client orders in Europe and the UK.

Therapeutic areas: OncologyMetabolic DisordersNephrologyImmunologyHematologyNeurology
Modalities: Monoclonal antibodies (mAbs)Vaccine antigens
Industry: Biotech

Drug pipeline

1 asset

MabionCD20

Partnerships

Novavax (vaccine antigen production including COVID/Omicron/influenza combo vaccines)Sartorius (biopharmaceutical development cooperation)WPD PharmaceuticalsIBMP [Brazil]EBRD loan partnership [European Bank for Reconstruction & Development]

Beyond the preview

Go deeper on Mabion S.A..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mabion S.A..